Royal Bank of Canada’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10
| Closed | – | – | 8005 |
|
|
2023
Q1 | $0 | Buy |
10
+6
| +150% | +$23 | ﹤0.01% | 7855 |
|
|
2022
Q4 | $0 | Sell |
4
-4
| -50% | -$24 | ﹤0.01% | 8096 |
|
|
2022
Q3 | $0 | Buy |
+8
| New | +$97 | ﹤0.01% | 8166 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7402 |
|
|
2020
Q3 | – | Sell |
-66
| Closed | -$5.89K | – | 7094 |
|
|
2020
Q2 | $9K | Hold |
66
| – | – | ﹤0.01% | 5882 |
|
|
2020
Q1 | $3K | Buy |
66
+7
| +12% | +$685 | ﹤0.01% | 6239 |
|
|
2019
Q4 | $7K | Sell |
59
-1
| -2% | -$135 | ﹤0.01% | 6269 |
|
|
2019
Q3 | $7K | Buy |
60
+2
| +3% | +$403 | ﹤0.01% | 5920 |
|
|
2019
Q2 | $17K | Hold |
58
| – | – | ﹤0.01% | 5797 |
|
|
2019
Q1 | $26K | Buy |
58
+44
| +314% | +$19.3K | ﹤0.01% | 5534 |
|
|
2018
Q4 | $6K | Buy |
+14
| New | +$8.68K | ﹤0.01% | 6124 |
|
|
2018
Q3 | – | Sell |
-75
| Closed | -$49.5K | – | 7073 |
|
|
2018
Q2 | $44K | Buy |
75
+53
| +241% | +$34.6K | ﹤0.01% | 5212 |
|
|
2018
Q1 | $14K | Buy |
+22
| New | +$16.5K | ﹤0.01% | 5600 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7039 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7094 |
|
Royal Bank of Canada's HTGM Position: Q2 2023 in Review
Royal Bank of Canada sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 10 shares.
Royal Bank of Canada first reported a position in HTGM in Q1 2018 and held it in 12 quarters. The position peaked at $44K in Q2 2018. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- Royal Bank of Canada reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Royal Bank of Canada sold 10 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023.
- Royal Bank of Canada first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 12 quarters.
- Royal Bank of Canada's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $44K in Q2 2018.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.